ライフサイエンスコーパス: release factor

1 UPF1, SMG1 kinase, SMG8, SMG9 and eukaryotic release factors).

2 retains its normal function as a translation release factor.

3 complex that may function as a peptidoglycan release factor.

4 12 N terminus functions to bind host vesicle release factors.

5 imited by truncation due to competition with release factors.

6 ensuring termination with either of the two release factors.

7 atically inhibit rates of peptide release by release factors.

8 induced by the stress hormone, corticotropin releasing factor.

9 alize with the stress hormone, corticotropin releasing factor.

10 were depolarised by exogenous corticotrophin releasing factor.

11 mone 44 (DH44), an ortholog of corticotropin-releasing factor.

12 ease factor complex that includes eukaryotic release factor 1 (eRF1) and eRF3.

13 he interaction between MoMLV RT and peptidyl release factor 1 (eRF1).

14 catalytic activity stimulated by eukaryotic release factor 1 (eRF1).

15 saturating and limiting levels of eukaryotic release factor 1 (eRF1).

16 ized by two similar class 1 release factors, release factor 1 (RF1) and release factor 2 (RF2).

17 recoded strains of Escherichia coli lacking Release Factor 1 (RF1) are becoming increasingly popular

18 3.1-A crystal structure of Escherichia coli release factor 1 (RF1) bound to the 70S ribosome in resp

19 acids (nnAAs) is limited by competition with release factor 1 (RF1).

20 UAA codons, which permitted the deletion of release factor 1 and reassignment of UAG translation fun

21 Deletion of release factor 1 in Escherichia coli enhances translatio

22 cherichia coli that lacks all TAG codons and release factor 1, endowing this organism with the orthog

23 It interacts with a translation-release factor 1-like protein Dom34/Pelota to direct dec

24 Interestingly, the release factor 1-specific codon TAG maintains a more or

25 s any endogenous in-frame UAGN sequences and release factor 1.

26 hrough by silencing expression of eukaryotic release factors 1 and 3 (eRF1 and eRF3) or by introducin

27 de), D2R agonist (quinpirole), corticotropin-releasing factor 1 (CRF1) antagonist (antalarmin), and a

28 ne domains of the glucagon and corticotropin releasing factor 1 (CRF1) receptors to develop improved

29 Ablation of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1), a neuronal activator of R

30 examined the role of Ras Guanine Nucleotide Releasing Factor 1 (RasGRF1) and 2 (RasGRF2), upstream r

31 n of Ras protein-specific guanine nucleotide releasing factor 1 (RasGrf1), a Ras activator (5-fold, P

32 with Ras protein-specific guanine nucleotide-releasing factor 1 (RASGRF1), leading to impaired activa

33 s to palatable food results in corticotropin-releasing factor-1 (CRF1) receptor antagonist-reversible

34 don in the A site by specifically recruiting release factor 2 (RF2), initially in a compact preaccomm

35 release factors, release factor 1 (RF1) and release factor 2 (RF2).

36 26907 in the ras-specific guanine-nucleotide releasing factor 2 (RASGRF2) gene, encoding a protein th

37 e processes; Ras-specific guanine nucleotide releasing factor 2 (RasGRF2).

38 ene (Ras protein-specific guanine nucleotide-releasing factor 2) with all clinical events except stro

39 Eukaryotic peptide release factor 3 (eRF3) is a conserved, essential gene i

40 o sterically occlude the binding of peptidyl release factor 3 (eRF3) to eRF1.

41 Normally, during termination, the class 2 release factor 3 (RF3), a GTPase, functions downstream o

42 nslation initiation factor 4G and eukaryotic release factor 3a (eRF3a).

43 After considering the releasing factor (66.6%) from the swab, the final accura

44 parameters set based on the distribution of release factors across facilities.

45 re termination, including the stimulation of release factor activity and the dissociation and recycli

46 ated by PTRF (polymerase I transcription and release factor, also known as cavin-1), which has previo

47 trongly inhibits peptidyl-tRNA hydrolysis by release factors and, to a lesser extent, peptide bond fo

48 ess neurotransmitters, such as corticotropin-releasing factor and dynorphin, in the neurocircuitry of

49 ing by increased expression of corticotropin-releasing factor and its feedback regulation of TLR4 exp

50 stress and resilience, such as corticotropin-releasing factor and nociceptin, has been postulated to

51 ism in the brain to counteract corticotropin-releasing factor and/or stress.

52 cretin/orexin, norepinephrine, corticotropin-releasing factor, and cytokines.

53 ral stress response induced by corticotropin releasing factor, and promoting stress resilience.

54 PA axis-based interventions of corticotropin-releasing factor antagonists and the glucocorticoid rece

55 By sequestering the available release factors, Api promotes pervasive stop codon bypas

56 cal function in termination, both classes of release factor are also involved in a post peptidyl tran

57 Furthermore, pause release factors are frequently dysregulated in MS brain

58 (especially neuropeptide Y and corticotropin-releasing factor) are modulated by alcohol drinking duri

59 ion because they have one of the alternative release factors, ArfA or ArfB.

60 nascent peptide exit tunnel and trapping the release factor associated with a terminating ribosome.

61 ent of Siglec-9, 'educated' myeloid cells to release factors associated with determination of the tum

62 ression of PTRF (polymerase I and transcript release factor) associated selectively with their glucos

63 RAD and suggest that positioning this client-release factor at the retrotranslocation site may afford

64 Corticotropin releasing factor binding protein (CRF-BP) was originally

65 Corticotropin-releasing factor binds with high affinity to CRF recepto

66 ed Crk SH3 domain-binding guanine-nucleotide releasing factor (C3G) binding to CrkII, whereas inhibit

67 Infusion of hypothalamic-releasing factors can reactivate the thyroid axis in pat

68 nd asked whether SSc-injured epidermal cells release factors capable of promoting fibrosis.

69 ound that the availability of the functional release factor complex Sup45-Sup35 strongly influences t

70 c translational termination is mediated by a release factor complex that includes eukaryotic release

71 othalamus and primarily in non-corticotropin releasing factor-containing neurons of the bed nucleus o

72 os activation were observed in corticotropin releasing factor-containing neurons of the paraventricul

73 nical termination on stop codons, eukaryotic release factors contribute to cotranslational protein qu

74 BDNF signaling is mediated by corticotrophin-releasing factor (CRF) acting in the NAc.

75 We report that corticotropin-releasing factor (CRF) acts in the ventral tegmental are

76 gh it has long been known that corticotropin-releasing factor (CRF) and CRF receptors are prominent i

77 ion between the stress hormone corticotropin releasing factor (CRF) and glutamate release onto dopami

78 d to partially colocalize with corticotropin-releasing factor (CRF) and growth hormone-releasing horm

79 The stress neuropeptide corticotropin releasing factor (CRF) and its receptors (CRF-R1, CRF-R2

80 Release of the neuropeptides corticotropin-releasing factor (CRF) and orexin-A in the ventral tegme

81 Corticotropin-releasing factor (CRF) and the three related peptides ur

82 To investigate corticotropin-releasing factor (CRF) contributions to fear memory in L

83 Corticotropin releasing factor (CRF) coordinates the brains responses

84 elease the stress neuropeptide corticotropin-releasing factor (CRF) drive anxiety-like behaviors in r

85 the central extrahypothalamic corticotropin-releasing factor (CRF) expression is associated with str

86 enced by the highly conserved corticotrophin-releasing factor (CRF) family of peptides and receptors

87 The corticotropin-releasing factor (CRF) family of peptides includes CRF a

88 tin 2 (Ucn2), a peptide of the corticotropin-releasing factor (CRF) family, binds with high affinity

89 n of the stress neuromediator, corticotropin-releasing factor (CRF) has been implicated in these diso

90 levant PI cells identified the corticotropin-releasing factor (CRF) homolog, DH44, as a circadian out

91 e self-administration, reduced corticotropin-releasing factor (CRF) immunodensity in the paraventricu

92 k indicates a crucial role for corticotropin-releasing factor (CRF) in neurobiological responses asso

93 ole of the stress neurohormone corticotropin-releasing factor (CRF) in stress-induced binge eating in

94 work hypothesizing a role for corticotropin-releasing factor (CRF) in the IC during craving and rela

95 ed following overexpression of corticotropin-releasing factor (CRF) in the NAc of female and male rat

96 ggests that catecholamines and corticotropin-releasing factor (CRF) interact in a serial manner to ac

97 Corticotropin-releasing factor (CRF) is an important link between stre

98 The stress neuropeptide corticotropin releasing factor (CRF) is anxiogenic and is produced by

99 emonstrate that, in the vBNST, corticotropin releasing factor (CRF) is expressed in neurons that inne

100 Corticotropin-releasing factor (CRF) is expressed in the Ce, has a rol

101 Corticotropin releasing factor (CRF) is the primary mediator of stress

102 Corticotropin-releasing factor (CRF) mediates anxiogenic responses by

103 nous neuropeptide Y (NPY) and corticotrophin-releasing factor (CRF) modulate the responses of the bas

104 Corticotrophin-releasing factor (CRF) modulates the influence of stress

105 alcohol exposure contains ~80% corticotropin-releasing factor (CRF) neurons and that the optogenetic

106 gh it has long-been known that corticotropin-releasing factor (CRF) neurons are prominent within the

107 on, potentially by activating corticotrophin releasing factor (CRF) neurons in the anterolateral cell

108 d activates a subpopulation of corticotropin-releasing factor (CRF) neurons in the bed nucleus of the

109 of an intravenous injection of corticotropin-releasing factor (CRF) on fructose malabsorption and the

110 nce of the stress neuropeptide corticotropin-releasing factor (CRF) on these responses.

111 ry but did not increase either corticotropin-releasing factor (CRF) or corticosterone.

112 Corticotropin-releasing factor (CRF) orchestrates the stress response,

113 The corticotropin-releasing factor (CRF) plays a key role in a variety of

114 derable evidence suggests that corticotropin-releasing factor (CRF) plays an important role in regula

115 stress-associated neuropeptide corticotropin releasing factor (CRF) produces a profound and reliable

116 The corticotropin-releasing factor (CRF) receptor 1 (CRFR1) is a target fo

117 eta elevation are dependent on corticotropin-releasing factor (CRF) receptor 1 signaling and an intac

118 awal was mediated by increased corticotropin releasing factor (CRF) receptor-1 expression and signall

119 Corticotropin-releasing factor (CRF) receptors are found in stress-rel

120 Because corticotropin-releasing factor (CRF) receptors are implicated, we comp

121 emonstrated that activation of corticotropin-releasing factor (CRF) receptors in the caudal dorsomedi

122 Corticotropin-releasing factor (CRF) receptors-which bind the hormone

123 Corticotropin releasing factor (CRF) regulates physiological and behav

124 e stress-related neuropeptide, corticotropin-releasing factor (CRF) regulates the dorsal raphe nucleu

125 Corticotropin releasing factor (CRF) signaling and CRF neurons in the

126 Corticotropin-releasing factor (CRF) signaling at the CRF1 receptor (C

127 The corticotropin releasing factor (CRF) system in the central amygdala (C

128 The corticotropin releasing factor (CRF) system in the central amygdala (C

129 strated that activation of the corticotropin-releasing factor (CRF) system potentiates MC degranulati

130 The corticotropin-releasing factor (CRF) system, which is involved in stre

131 gdala (Neo-A) lesions on brain corticotropin-releasing factor (CRF) systems and hypothalamic-pituitar

132 Corticotropin-releasing factor (CRF) that is released from the paraven

133 The corticotropin-releasing factor (CRF) type 1 receptor (CRF1R) for the 4

134 Systemic blockade of corticotropin-releasing factor (CRF) type 1 receptors (CRFR1s) reduces

135 Corticotropin releasing factor (CRF) within the ventral tegmental area

136 ng peptide, PAC1 receptor, and corticotropin-releasing factor (CRF), (CRF1) receptor.

137 We investigated how corticotrophin releasing factor (CRF), a critical stress response media

138 Here we report that corticotropin-releasing factor (CRF), a neuropeptide released in respo

139 e number of neurons expressing corticotropin releasing factor (CRF), a neuropeptide that has a promin

140 ited different sensitivity to corticotrophin-releasing factor (CRF), a stress hormone that has been i

141 this, the CEA highly expresses corticotropin-releasing factor (CRF), an important modulator of stress

142 opeptide related to vertebrate corticotropin-releasing factor (CRF), and its receptor, Dh44R1.

143 is thought to communicate via corticotropin-releasing factor (CRF), but studies have yet to examine

144 The neuropeptide, corticotropin-releasing factor (CRF), coordinates the physiological an

145 es indicate the involvement of corticotropin-releasing factor (CRF), noradrenaline, dopamine, glutama

146 s for the stress neuropeptide, corticotropin-releasing factor (CRF), that render the locus coeruleus

147 Corticotropin-releasing factor (CRF), the major stress peptide in the

148 e focus is on the receptor for corticotropin-releasing factor (CRF), the orchestrator of the stress r

149 Corticotropin-releasing factor (CRF), the stress-related neuropeptide,

150 ticotropes are stimulated with corticotropin releasing factor (CRF), whereupon SSTR2 exits the compar

151 g the stress-sensitive peptide corticotropin-releasing factor (CRF), which has been identified in cri

152 oradrenergic substrates [via a corticotropin-releasing factor (CRF)-dependent mechanism] that regulat

153 nd inhibitory transmission in corticotrophin-releasing factor (CRF)-expressing dorsal-medial (mpd) ne

154 Here, we demonstrate that corticotrophin-releasing factor (CRF)-expressing neurons in the central

155 en shown previously to cause a corticotropin-releasing factor (CRF)-mediated increase in tonic locus

156 Corticotropin-releasing factor (CRF)-mediated mechanisms in the bed nu

157 in the brain that counteracts corticotropin-releasing factor (CRF)-mediated stress and anxiety sympt

158 D is functionally expressed on corticotropin-releasing factor (CRF)-positive BNST cells implicated in

159 uding neuropeptide Y (NPY) and corticotropin-releasing factor (CRF).

160 the stress-sensitive peptide, corticotropin releasing factor (CRF).

161 ocorticoid receptors (GRs) and corticotropin-releasing factor (CRF).

162 opaminergic neurons expressing corticotropin-releasing factor (CRF).

163 e prototypical stress hormone, corticotropin releasing factor (CRF).

164 e stress-related neuropeptide, corticotropin-releasing factor (CRF).

165 the anxiogenic neuromodulator, corticotropin releasing factor (CRF).

166 l antibody, CTRND05, targeting corticotropin-releasing factor (CRF).

167 that produce the neuropeptide corticotropin-releasing factor (CRF).

168 tested the hypothesis that the corticotropin-releasing factor (CRF1) antagonist GSK561679 differentia

169 T proteins function mechanistically as pause-release factors critical to expression of genes that are

170 sult in a tangible model disclosing how hPSC-released factors deflect CHIR99021-induced lineage commi

171 tment of brain stress systems (corticotropin-releasing factor, dynorphin, norepinephrine, hypocretin,

172 ly on an evolutionarily unrelated omnipotent release factor (eRF1) to recognize all three stop codons

173 the complex functional interplay between two release factors, eRF1 and eRF3, in which GTP hydrolysis

174 Downregulation of translation release factor eRF3 or eRF1 reduced SFL-mediated prematu

175 nal domain with eukaryotic polypeptide chain release factor, eRF3.

176 cy of competition for the stop codon between release factors (eRFs) and near-cognate tRNAs is largely

177 teral amygdala (BLA) away from corticotropin releasing factor-expressing (CRF(+)) centrolateral amygd

178 neuropeptides vasopressin and corticotropin-releasing factor facilitate, while serotonin inhibits, a

179 rs, which bind peptides of the corticotropin releasing factor family and are key mediators in the str

180 Release factor homolog C12orf65 (mtRF-R) and RNA binding

181 al. provide a causal link between histamine-releasing factor (HRF) interactions with IgE and food al

182 lacks a secreted factor related to histamine-releasing factor (HRF).

183 Histamine-releasing factor (HRF; also known as translationally con

184 ther suggest that an activated corticotropin-releasing factor/hypothalamic-pituitary-adrenal axis sys

185 discovered that UPF3B (i) interacts with the release factors, (ii) delays translation termination and

186 thropin-releasing hormone, and corticotropin-releasing factor immunoreactive cells in the paraventric

187 ned in vitro system, we explored the role of release factors in canonical termination and post PT QC.

188 l axis, including signaling by corticotropin-releasing factor, in the pathophysiology of PTSD.

189 A1 and aromatase enhanced local bone marrow-releasing factors, including androgen receptor, estrogen

190 Corticotropin-releasing factor infusions into LA impair the consolidat

191 Corticotropin-releasing factor infusions into the central nucleus of t

192 suggests muscle contractions during exercise release factors into the blood which cross into the brai

193 In preeclampsia, the placenta releases factors into the maternal circulation that caus

194 The variability of refinery subprocess release factors is characterized using log-normal distri

195 While corticotrophin releasing factor is the prototypic member of this class,

196 p codons, suggesting a general mechanism for release-factor-mediated translational termination in whi

197 cting to vasopressinergic and corticotrophin releasing factor neurons in the paraventricular nucleus,

198 acts with the neuromodulators, corticotropin-releasing factor, norepinephrine, dopamine, and serotoni

199 e cell, thereby establishing its function as release factor of mislocalized palmitoylated proteins in

200 l impact of treatment with such hypothalamic releasing factors on recovery from critical illness as w

201 ess of the way PoTC was prepared with either release factors or puromycin.

202 ss of Upf (up-frameshift) factors, defective release factors, or the presence of the aminoglycoside g

203 ior hypothalamus that may gate corticotropin-releasing factor output from the amygdala to the anterio

204 d (i.e., serotonin, dynorphin, corticotropin-releasing factor, oxytocin).

205 pluripotency genes by dissociating the pause release factor P-TEFb from an inactive complex containin

206 Active transcription starts when the pause release factor P-TEFb is recruited to initiate productiv

207 leading to recruitment of BRD4 and the pause release factor P-TEFb, followed by productive elongation

208 Cohesin dynamics are controlled by the releasing factors Pds5 and Wapl and the cohesin stabiliz

209 ed competition between ternary complexes and release factors perturbs the UGA readthrough level.

210 appetite regulation, including corticotropin releasing factor, pro-opiomelanocortin B, and glucose tr

211 The eukaryotic release factor protein family has also been dramatically

212 Similarly, polymerase I transcript release factor (PTRF) deficiency resulted in decreased i

213 Cavin-1/polymerase I and transcript release factor (PTRF) is a requisite component of caveol

214 logical consequence of central corticotropin-releasing factor receptor (CRF-R) activation.

215 ed differential involvement of corticotropin-releasing factor receptor (CRFR) 1 and 2 in acute stress

216 haracterize the effects of the corticotropin-releasing factor receptor 1 (CRF-R1) antagonist, GW87600

217 (NE) receptors (alpha1) via a corticotropin-releasing factor receptor 1 (CRF-R1)-dependent mechanism

218 g the efficacy of GSK561679, a corticotropin-releasing factor receptor 1 (CRF1 receptor) antagonist i

219 Blockade of corticotropin-releasing factor receptor 1 (CRF1) suppresses stress-ind

220 member of a class B GPCR, the corticotropin releasing factor receptor 1 (CRF1R).

221 what has been observed for the corticotropin-releasing factor receptor 1 (CRFR1), SAP97 expression is

222 r-activated receptor gamma and corticotropin-releasing factor receptor 1 were notable exceptions.

223 ed significant upregulation of corticotropin releasing factor receptor 2 (CrfR2) in the amygdala of m

224 constitutive activation of the corticotropin-releasing factor receptor family homologue SEB-3.

225 d psychological stress through corticotropin-releasing factor receptor subtype 1 (CRF(1)) expressed o

226 dy we investigated the role of corticotropin-releasing factor receptor subtype 2 (CRF(2)) as a modula

227 ent study examines the role of corticotropin releasing factor receptor subtypes 1 and 2 (CRFR1, CRFR2

228 CRF(2(a))R and the homologous corticotropin-releasing factor receptor type 1 (CRF(1)R) possessing a

229 vestigated whether blockade of corticotropin-releasing factor receptor type 1 (CRF-R1) could prevent

230 ctions in anandamide driven by corticotropin-releasing factor receptor type 1 (CRF1) potentiation of

231 re the interaction between the corticotropin releasing factor receptor type 1 (CRF1R) and its native

232 ed interactions of the class B corticotropin-releasing factor receptor type 1 (CRF1R) with two peptid

233 Corticotropin-releasing factor receptor type 1 (CRFR1) is involved in

234 compartments, we show that the corticotropin-releasing factor receptor type 1 has a specific monomer/

235 nsmembrane domain of the human corticotropin-releasing factor receptor type 1 in complex with the sma

236 The corticotropin-releasing factor receptor type 1 is a class B receptor w

237 librium is established for the corticotropin-releasing factor receptor type 1.

238 Corticotropin-releasing factor receptor type 2 (CRFR2) has been implic

239 central stress response, while corticotropin-releasing factor receptor type 2 (CRFR2) has been sugges

240 bserved abnormal expression of corticotropin-releasing factor receptor type 2 (CRFR2) to be associate

241 The corticotropin-releasing factor receptor type 2a (CRF(2(a))R) possesses

242 is unaffected by alpha1-AR and corticotropin-releasing factor receptor-1 (CRFR(1)) antagonists, but i

243 tention were attenuated by the corticotropin-releasing factor receptor-1 antagonist antalarmin but no

244 Corticotropin-Releasing Factor Receptors (CRFRs) are class B1 G-protei

245 Corticotropin-releasing factor receptors (CRFRs), class B G protein-co

246 Codon selection, releasing factor recognition sequence and specific intro

247 Release factors recognize stop codons in the ribosomal A

248 uential ATPase and GTPase activities license release factors Rei1 and Yvh1 to trigger Arx1 and Mrt4 r

249 it has been shown to increase corticotropin-releasing factor release in extrahypothalamic brain regi

250 codons are recognized by two similar class 1 release factors, release factor 1 (RF1) and release fact

251 osome encounters a stop codon, it recruits a release factor (RF) to hydrolyze the ester bond between

252 steady state amount of mRNA and protein for release factors RF1 and RF2 during exponential growth.

253 ion-like protein (RepA-WH1) into the E. coli releasing factor RF1 promotes its aggregation and enable

254 Stop codons are recognized by class I release factors (RF1 and RF2 in Escherichia coli), which

255 ecognizes stalled ribosomes and recruits the release factor RF2, which catalyses the termination of p

256 mes stalled on truncated mRNAs by recruiting release factor RF2, which normally binds stop codons to

257 tion in Bacteria and Archaea is initiated by release factors (RFs) 1 or 2 recognizing a stop codon in

258 Release factors (RFs) decode the stop codon, hydrolyze p

259 of the specificity of the bacterial class I release factors (RFs) in decoding stop codons has evolve

260 Alterations in central corticotropin-releasing factor signaling pathways have been implicated

261 In addition to this strain release factor, steric and inductive effects contribute

262 forces and an inflammatory microenvironment release factors such as a disintegrin and metalloprotein

263 n-gamma (IFN-gamma) and induce cytolysis via releasing factors such as perforin, which permeabilizes

264 Moreover, Tia1/Pub1 acts cooperatively with release factor Sup35/eRF3 to establish a two-protein sel

265 Here, we examined how the canonical release factors Sup45-Sup35 (eRF1-eRF3) and their paralo

266 s), (4) the (gastrointestinal) corticotropin-releasing factor system, and (5) the intestinal response

267 s probed using a dexamethasone/corticotropin-releasing factor test.

268 de the kinase domain constitute a nucleotide release factor that likely interacts with the small lobe

269 For example, apoptotic cells can release factors that influence the proliferation and sur

270 jor differentially activate keratinocytes to release factors that limit infection in monocytes.

271 fibroblasts overexpress matrix proteins and release factors that promote further recruitment of acti

272 w that mast cells sense colder temperatures, release factors that promote UCP1 expression, and are an

273 p53-expressing senescent stellate cells release factors that skew macrophage polarization toward

274 The TNFalpha-activated PAEC released factors that induce huTreg chemotaxis, partiall

275 ontrol of the pathogen, but B. dendrobatidis releases factors that inhibit in vitro and in vivo lymph

276 spected of initiating childhood leukaemia by releasing factors that cause DNA damage in cord blood an

277 strocytes play a key role in this process by releasing factors that promote the formation of excitato

278 role in maintaining vascular homeostasis by releasing factors that regulate local blood flow, system

279 counteracting the functions of corticotropin-releasing factor, the primary stress-mediating neuropept

280 lin, nesfatin-1, somatostatin, corticotropin-releasing factor, thyrotropin-releasing hormone and calc

281 During normal translation, the binding of a release factor to one of the three stop codons (UGA, UAA

282 buting ions, removing neurotransmitters, and releasing factors to influence blood flow and neuronal a

283 Corticotropin releasing factor type 1 (CRF1) is a key component in the

284 Activation of corticotropin-releasing factor type 1 (CRF1) receptors in the CeA play

285 ve effect is mediated via the corticotrophin-releasing factor type 1 receptor (CRF1R, also known as C

286 peated social stress decreased corticotropin-releasing factor type 1 receptor and increased mu-opioid

287 We found that corticotropin-releasing factor type 1 receptor within the paraventricu

288 LTCC-based mechanism; instead, corticotropin-releasing factor type 1 receptors (CRF1s) mediate alcoho

289 LTCC-based mechanism; instead, corticotropin-releasing factor type 1 receptors (CRF1s) mediate alcoho

290 The corticotropin-releasing factor type 2 receptor (CRFR2) is suggested to

291 hat the mechanism involved the corticotropin-releasing factor type 2 receptor, cAMP elevation, and ac

292 We identify an FxxP motif in the cohesin release factor WAPL and show that this regulates WAPL ph

293 Here we report that the cohesin release factor WAPL creates a pool of free cohesin, in a

294 Conversely, the cohesin-release factor Wapl(13,14) restricts loop extension(10,1

295 ified cohesin ligands, including the cohesin release factor WAPL(2,3).

296 hesin with chromatin depends on WAPL cohesin release factor (WAPL) and on PDS5 cohesin-associated fac

297 ion of diverse microbial moieties, including released factors, which modulate host immune responses t

298 ombined administration of those hypothalamic releasing factors, which have been identified as suppres

299 complexes on DNA by antagonizing the cohesin release factor Wings-apart like protein (Wapl).

300 cteria decode stop codons using two separate release factors with differing specificities for the sec